ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C reactive protein/albumin ratio (CAR) is considered as a predictor for prognosis in a variety of systemic disorders including malignancies. We aimed to investigate the potential impact of pretransplant CAR on transplant related complications and clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 430 alloHSCT recipients [median age: 44(18-72) years; male/female: 258/172] were included in this retrospective study. Median follow-up period was 761(1-5910) days. The study population was divided into two subgroups as low- (< 0.312) and high-CAR (≥ 0.312) [AUC: 0.61 (95%CI: 0.55-0.67);
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.